Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4

Summary

MITO END-4 is a prospective, single arm, multicentric phase II trial aiming to assess whether Inavolisib is effective in the treatment of advanced endometrial carcinoma with pathogenic PIK3CA mutation. Approximately 48 patients with PIK3CA mutation will be overall enrolled in the study.

Timeline

Start

2026-05

Primary completion

2030-05

Completion

2030-05

Drugs

Indications